Index

Note: Page numbers of article titles are in boldface type.

A

Acid-base changes
  bicarbonate therapy and, 344
Acid-base disorders
  compensation for, 313–323
    calculation of expected, 319–321
    concept of, 313–314
    metabolic acidosis, 315–317
    metabolic alkalosis, 317–318
    physiology of, 314–321
    respiratory acidosis, 318
    respiratory alkalosis, 318–319
  electrolytes and, 511–512
  quick reference on, 191–196 See also Anion gap; Strong ion gap
    respiratory in CCU, 351–357 See also Respiratory acid-base disorders, in CCU
Acidosis
  lactic
    bicarbonate therapy for, 346
  metabolic, 201–203, 315–317 See also Metabolic acidosis
  paradoxic intracellular
    bicarbonate therapy and, 344
  respiratory, 185–189, 318, 354–355 See also Respiratory acidosis
Adrenergic effect
  type B1 hyperlactatemia and, 332
Albumin
  controversies related to, 412–415
  in fluid therapy
    controversies related to, 368–369
Alkalosis
  metabolic, 197–200, 317–318 See also Metabolic alkalosis
  respiratory, 181–184, 318–319, 355–356 See also Respiratory alkalosis
Analytical errors
  in mineral and electrolyte analysis, 263–272 See also Electrolyte(s); Mineral(s)
Anemia(s)
  hemolytic
    preanalytical errors and abnormalities related to, 267
  hyperlactatemia and, 331
Anesthesia
  colloids vs. crystalloids during, 428
  fluid rates during, 427–428
  maintenance fluid therapy in, 392–393
Anion gap
- analysis of, 194–195
- changes in, 195–196
- introduction, 205–206
- quick reference on, 192–194

B
Bicarbonate-losing diseases
- bicarbonate therapy for, 347
Bicarbonate therapy, 343–349
- adverse effects of, 344–346
- benefits of, 344
- indications for, 346–347
- introduction, 343
Bisphosphonates
- in feline ionized hypercalcemia management, 285–286
Blood products
- controversies related to, 412–415
  - albumin, 412–415
  - plasma, 413
Brain disease
- in CCU
  - respiratory acid-base disorders and, 353–354

C
Calcimemetics
- in feline ionized hypercalcemia management, 286
Calcium
- decreased
  - in feline ionized hypercalcemia management, 283–284
  - disturbances of
    - perioperative fluid therapy and, 432–433
  - ionized
    - described, 273–274
Calcium metabolic hormones
- in feline ionized hypercalcemia evaluation, 278–279
Cancer(s)
- lung
  - metastatic
    - fluid therapy for, 467
Canned diets
- in feline ionized hypercalcemia management, 283
Carbon dioxide tension
- control of
  - in CCU, 352
Cardiopulmonary resuscitation
- bicarbonate therapy for, 346–347
Cardiovascular system
- respiratory acid-base abnormalities effects on, 353
Cat(s)
- ionized hypercalcemia in, 273–292  See also Feline ionized hypercalcemia

CCU
- See Critical care unit (CCU)

Children
- fluid therapy in, 373–382  See also Fluid therapy, for pediatric patients

Chloride, 219–222
- abnormalities of
  - analysis of, 219–220
  - corrected
    - hyperchloremia after, 221–222
    - hypochloremia after, 221
    - in metabolic acidosis, 202
    - normochloremia after, 221
  - in kidney disease
    - management of, 481
- quick reference on, 219–222

Coagulopathy
- trauma-induced
  - fluid therapy and, 402

Colloid(s), 411–421
- controversies related to, 411–421
  - blood products, 412–415
  - discussion, 417–418
  - introduction, 411–412
  - synthetic colloids, 415–417
- crystalloids vs.
  - during anesthesia, 428
  - in fluid therapy, 361–363
- synthetic
  - controversies related to, 415–417
  - in fluid therapy
    - controversies related to, 368–369

Compartmentalization
- in fluid and electrolyte therapy during vomiting and diarrhea, 508

Compensation
- for acid-base disorders, 313–323  See also Acid-base disorders
  - calculation of expected, 319–321
  - concept of, 313–314
  - physiology of, 314–321

Contrast-induced nephropathy
- bicarbonate therapy for, 347

Critical care unit (CCU)
- respiratory acid-base disorders in, 351–357  See also Respiratory acid-base disorders, in CCU

Crystalloid(s)
- in fluid therapy, 361
  - for vomiting and diarrhea, 512

Crystalloid infusion
- isotonic
  - in DCR, 406–407
D

Damage control resuscitation (DCR)
  limited isotonic crystalloid infusion in, 406–407
  in trauma patients, 405–407

DCR
  See Damage control resuscitation (DCR)

Dehydration
  hypovolemia vs.
    in fluid therapy, 363
    vomiting and diarrhea and, 508–511

Delayed resuscitation
  fluid therapy in trauma patients and, 404

Dextran
  controversies related to, 417

Diabetic ketoacidosis (DKA)
  bicarbonate therapy in, 346
  defined, 491
  fluid and electrolyte therapy in, 491–503
    considerations, 497–498
    fluid rates and administration, 495–497
    fluid types, 493–493
    insulin therapy, 494–495
    introduction, 491
    overview of, 492
    supplementation of electrolytes and dextrose, 498–502
  nonpharmacologic management of, 492
  pathophysiologic management of, 491–492

Diarrhea
  fluid and electrolyte therapy during
    combination therapy, 515–516
    crystalloid fluid, 512
    for dehydration, 508–511
    introduction, 506–508
    requirements, 514–515
    route of, 512–514
    TBW and compartmentalization, 508
    treatment failure, 516–517
    updates on, 516

Diet(s)
  in feline ionized hypercalcemia management, 282–283 See also specific types, e.g., Urolithiasis diet

DKA
  See Diabetic ketoacidosis (DKA)

Drug(s)
  hyperlactatemia-associated, 333
  ILE–sensitive, 438
  preanalytical errors and abnormalities related to, 269

Dry diets
  in feline ionized hypercalcemia management, 283
E

Edema
  isotonic fluids and, 388–389
  pulmonary
    evaluation of, 462–464

Electrolyte(s)
  acid-base disorders and, 511–512
  analysis of
    postanalytical factors
      error-related, 269
    preanalytical findings, 264–269
      physiologic conditions affecting, 267–269
    sample handling and management, 265–267
  results of, 263–272
    errors in, 269
  changes in
    respiratory acid-base abnormalities and, 353
    need for, 385

Electrolyte disturbances
  perioperative fluid therapy and, 428–429

Endothelial glycocalyx, 360

Extravascular lung water
  in evaluation of pulmonary edema/volume overload, 463–464

F

Feline ionized hypercalcemia, 273–292
  clinical signs of, 277–278
  differential diagnosis of, 276–277
  evaluation of, 277–280
    calcium metabolic hormones in, 278–279
    future directions in, 279–280
    physical examination in, 277–278
    ultrasound in, 278
    USG in, 278
  introduction, 273–274
  laboratory analysis of, 274–276
  treatment of, 280–288
    complications of, 286–287
    long-term recommendations in, 288
    nonpharmacologic, 280–284
    outcome evaluation, 288
    overview of, 280
    pharmacologic agents in, 284–286
    resistance to, 286–287

Fiber
  in feline ionized hypercalcemia management, 280–282

Fluid additives
  in fluid therapy, 366–367
Fluid and electrolyte disorders
  in kidney disease, 471–490 See also Kidney disease, fluid and electrolyte disorders in
Fluid and electrolyte therapy
  in DKA, 491–503 See also Diabetic ketoacidosis (DKA)
during vomiting and diarrhea, 505–519 See also Diarrhea; Vomiting
Fluid therapy, 359–371
  colloids in, 361–363
  controversies related to, 368–369
  crystalloids in, 361
  early goal-directed therapy, 365–366
  endothelial glycocalyx, 360
  in feline ionized hypercalcemia management, 286
  fluid additives in, 366–367
for fluid and electrolyte disorders in kidney disease, 472–480
  assessing hydration in, 472–473
  converting oliguria to nonoliguria in, 477–479
  discontinuation of, 479–480
  fluid types in, 474
  in hospitalized patients, 472
  monitoring of, 479
  outpatient, 480
  route of administration in, 473
  volume and rate of, 474–476
in heart disease, 465–466
  hypotensive resuscitation in, 365
  hypovolemia vs. dehydration in, 363
for ILDs, 467
  introduction, 359
in lung disease, 461–470 See also specific diseases
  evaluation for pulmonary edema/volume overload, 462–464
  goal-directed therapy and biomarkers for, 464–465
  overview of, 461–462
  right heart function effects of, 464
maintenance of, 383–395
  in anesthesia, 392–393
  clinical approach to, 389–392
  in health, 384–385
  in health vs. illness, 385–387
  introduction, 383–384
  isotonic vs. hypotonic fluids, 387
for metastatic lung cancer, 467
  monitoring of, 367–368
for pediatric patients, 373–382
  described, 376–377
  discontinuation of, 380–381
  dosage of, 379–380
  introduction, 373–375
  physiology of, 375–376
  routes of administration of, 377–379
perioperative, 423–434
  calcium disturbances and, 432–433
colloids vs. crystalloids during anesthesia, 428
electrolyte disturbances and, 428–429
in hemodynamic stability, 424–425
introduction, 423–424
monitoring of, 425–427
potassium abnormalities and, 430–432
rates during anesthesia, 427–428
sodium abnormalities and, 429–430
for pleural space disease, 467–468
for pneumonia, 467
for pulmonary contusion, 466–467
for pulmonary thromboembolism, 468
route of administration of, 363–364
Starling forces in, 359–360
tissue safety factors in, 360–361
in trauma patients, 397–410 See also Trauma patients, fluid therapy in volume and rate of administration of, 364–365

G

Gelatins
  controversies related to, 417
Glucocorticosteroids
  in feline ionized hypercalcemia management, 284–285
Glycocalyx
  endothelial, 360

H

Heart disease
  fluid therapy for, 465–466
Hemodynamic stability
  perioperative fluid therapy in, 424–425
Hemolytic anemia
  preanalytical errors and abnormalities related to, 267
Hemorrhage
  controlled vs. uncontrolled
    impact on fluid resuscitation in trauma patients, 399
Hemorrhagic shock resuscitation
  goals of, 398
Hemostatic resuscitation
  DCR in, 406
HES solutions
  See Hydroxyethyl starch (HES) solutions
High anion gap metabolic acidosis, 205–207
  analysis of, 206
  causes of, 206–207
  clinical signs of, 207
  introduction, 205–206
  quick reference on, 205–207
Hydroxyethyl starch (HES) solutions
controversies related to, 415–417

Hypercalcemia, 241–248
analysis of, 242
causes of, 242–244
diagnostic approach to, 244, 245
introduction, 241
ionized
clinical signs of, 244
feline, 273–292 See also Feline ionized hypercalcemia
quick reference on, 241–248
treatment of, 244, 246, 247

Hyperglobulinemia
preanalytical errors and abnormalities related to, 268

Hyperkalemia, 223–228
analysis of, 224–227
approach to, 227
causes of, 227
clinical signs of, 227
introduction, 223–224
in kidney disease
management of, 482–484
perioperative fluid therapy and, 430–431
quick reference on, 223–228

Hyperlactatemia
absolute type A
decreased oxygen delivery with, 329–331
anemia and, 331
clinical approach to, 327–329
evaluation of
lactate results interpretation in, 329
patient assessment in, 327
sample collection and processing in, 327–329
hypoxemia and, 331
relative type A
increased oxygen demand with, 331
sepsis and, 331
shock and, 329–331
type B1, 331–333
type B2
drugs or toxins in, 333
type B3
inborn errors of metabolism and, 333

Hyperlipidemia
preanalytical errors and abnormalities related to, 268

Hyernatremia, 209–212, 305–310
bicarbonate therapy and, 344–345
causes of, 210–211, 305
chronic
consequences of, 306
clinical signs of, 211–212, 305–306
described, 305
management of, 211–212
  case examples, 307–310
  principles of, 306
perioperative fluid therapy and, 429–430
quick reference on, 209–212
reference range and danger values associated with, 210
sodium distribution and, 209–210
water deficit calculations in, 306–307
Hyperphosphotemia, 259, 261–262
Hyperproteineinemia
  preanalytical errors and abnormalities related to, 268
Hypoalbuminemia, 451–459
  defined, 451
  evaluation of, 452–453
  introduction, 451
  preanalytical errors and abnormalities related to, 268–269
  treatment of, 451–459
    complications of, 456–457
    long-term recommendations in, 457
    nonpharmacologic, 455–456
    outcome of, 457
    pharmacologic, 453–455
Hypocalcemia, 249–256
  analysis of, 250
  causes of, 250, 251
  clinical signs of, 250, 252
  diagnostic approach to, 253
  introduction, 249
  perioperative fluid therapy and, 432–433
  quick reference on, 249–256
  treatment of, 253–255
Hypokalemia, 229–234
  analysis of, 229–230
  approach to, 233
  causes of, 230–232
  clinical signs of, 231
  introduction, 229
  in kidney disease
    management of, 481–482
    perioperative fluid therapy and, 431–432
  quick reference on, 229–234
Hyponatremia, 213–217, 296–305
  case examples, 300–305
  causes of, 214–216, 296–298
  chronic
    consequences of, 298
    clinical manifestations of, 298
    hypotonic fluids and, 387–388
    management of, 216–217, 300–305
    principles of, 299
Hyponatremia (continued)
  perioperative fluid therapy and, 430
  quick reference on, 213–217
  sodium deficit calculation in, 299–300
  sodium distribution and, 213–214
Hypophosphatemia, 259
Hypotension
  permissive
    DCR in, 405–406
    fluid therapy in trauma patients and, 403–404
Hypotensive resuscitation
  in fluid therapy, 365
  fluid therapy in trauma patients and, 403–404
  TBI related to
    in trauma patients, 404–405
Hypotonic fluids
  hyponatremia due to, 387–388
  isotonic fluids vs., 387
Hypovolemia
  dehydration vs.
    in fluid therapy, 363
Hypoxemia, 175–179
  analysis of, 176–177
  approach to, 178–179
  causes of, 177–178
  clinical signs of, 178
  hyperlactatemia and, 331
  introduction, 175
  quick reference on, 175–179

I
Icteric samples
  preanalytical errors and abnormalities related to, 267
ILDs
  See Interstitial lung diseases (ILDs)
ILEs
  See Intravenous lipid emulsions (ILEs)
Immunomodulation
  changes in
    respiratory acid-base abnormalities and, 353
Inborn errors of metabolism
  type B3 hyperlactatemia and, 333
Insulin therapy
  in DKA management, 494–495
Interstitial lung diseases (ILDs)
  fluid therapy for, 467
Intoxications
  lipid therapy for, 435–450 See also Lipid therapy, for intoxications; specific types and
  Intravenous lipid emulsions (ILEs)
Intravascular volume
increased
bicarbonate therapy and, 344–345

Intravenous lipid emulsions (ILEs)
characteristics of, 438
for intoxications, 435–450
characteristics of, 438
dosing of, 442–443
efficacy of, 438–443
permethrin, 439–442
side effects of, 443–445

Ionized calcium
described, 273–274

Isotonic crystalloid infusion
in DCR, 406–407

Isotonic fluids
hypotonic fluids vs., 387
volume overload and edema due to, 388–389

Ivermectin
intoxication of
ILEs for, 442

K
Ketoacidosis
diabetic See Diabetic ketoacidosis (DKA)

Kidney disease
bicarbonate therapy for, 347
fluid and electrolyte disorders in
management of, 471–490
calcium disorders, 484–485
fluid therapy in, 472–480 See also Fluid therapy, for fluid and electrolyte disorders in kidney disease
introduction, 471–472
magnesium disorders, 485
metabolic acidosis, 486
nutritional support in, 480–481
phosphorus disorders, 485
potassium disorders, 481–484
sodium and chloride disorders, 481

L
Lactate, 325–342. See also specific disorders related to, e.g., Hyperlactatemia
biochemistry of, 325–326
clinical use of, 325–342
introduction, 325
kinetics of, 327
as prognostic tool, 334–335
D-Lactate, 333–334
Lactic acid
biochemistry of, 325–326
Lactic acidosis
  bicarbonate therapy for, 346
Lactone(s)
  macrocyclic
    intoxication of
      ILEs for, 442
Leukocytosis
  preanalytical errors and abnormalities related to, 269
Lipemic samples
  preanalytical errors and abnormalities related to, 268
Lipid emulsions
  intravenous
    for intoxications, 435–450 See also Intravenous lipid emulsions (ILEs); Lipid therapy, for intoxications
Lipid shuttle
  from lipid sink to, 436–437
Lipid sink
  to lipid shuttle, 436
Lipid therapy
  for intoxications, 435–450 See also Intravenous lipid emulsions (ILEs)
    dosing of, 442–443
    efficacy of, 438–443
    introduction, 435–436
    mechanism of action of, 436–437
    side effects of, 443–445
Liposome-based nano-antidota, 437
Lung cancer
  metastatic
    fluid therapy for, 467
Lung compliance
  in evaluation for pulmonary edema/volume overload, 462–464
Lung disease(s)
  fluid therapy in, 461–470 See also specific diseases and Fluid therapy, in lung disease
    interstitial
      fluid therapy for, 467
Lung water
  extravascular
    in pulmonary edema/volume overload evaluation, 463–464

M

Macrocyclic lactones
  intoxication of
    ILEs for, 442
Magnesium, 235–239
  abnormalities of
    in kidney disease
      management of, 484–485
    analysis of, 236
    deficit of See Magnesium deficit
  excess of, 239
introduction, 235–236
quick reference on, 235–239

Magnesium deficit
approach to, 236, 238–239
causes of, 236, 237
clinical signs of, 236, 238

Magnesium excess, 239

Maintenance fluid therapy, 383–395. See also Fluid therapy, maintenance of

Mechanical ventilation
in CCU
respiratory acid-base disorders and, 354

Metabolic acidosis, 201–203
analysis of, 202
causes of, 202–203
clinical signs of, 203
compensation for, 315–317
corrected chloride in, 202
high anion gap metabolic acidosis
quick reference on, 205–207
introduction, 201–202
in kidney disease
management of, 486
quick reference on, 201–203

Metabolic alkalosis, 197–200
analysis of, 198–199
approach to, 200
causes of, 197, 199–200
clinical signs of, 200
introduction, 197
metabolic, 317–318
quick reference on, 197–200

Metastatic lung cancer
fluid therapy for, 467

Microcirculatory dysfunction
type B1 hyperlactatemia and, 331–332

Mineral(s)
analysis of
postanalytical factors
error-related, 269
preanalytical findings, 264–269
physiologic conditions affecting, 267–269
sample handling and management, 265–267
results of, 263–272
errors in, 269

Mitochondrial distress
type B1 hyperlactatemia and, 331–332

N

Nano-antidota
liposome-based, 437
Nephropathy
- contrast-induced bicarbonate therapy for, 347

Nervous system
- respiratory acid-base abnormalities effects on, 353

Nutritional support
- for fluid and electrolyte disorders in kidney disease, 480–481

O

Osmoregulation, 295–296
Oxygen
- decreased delivery of
  - in absolute type A hyperlactatemia, 329–331
Oxygen demand
- increased
  - in relative type A hyperlactatemia, 331

P

Paradoxic intracellular acidosis
- bicarbonate therapy and, 344

Pediatric patients
- fluid therapy in, 373–382 See also Fluid therapy, for pediatric patients

Perioperative fluid therapy, 423–434. See also Fluid therapy, perioperative

Permethrin
- intoxication of
  - ILEs for, 439–442

Permissive hypotension
- DCR in, 405–406
  - fluid therapy in trauma patients and, 403–404

Phosphorus, 257–262
- abnormalities of
  - analysis of, 258–259
  - hyperphosphatemia, 259, 261–262
  - hypophosphatemia, 259
  - in kidney disease
    - management of, 485
    - introduction, 257–258
  - quick reference on, 257–262

Plasma lactate
- clinical use of, 325–342 See also Lactate

Pleural space disease
- fluid therapy for, 467–468

Pneumonia
- fluid therapy for, 467

Potassium
- abnormalities of
  - in kidney disease
    - management of, 481–484
    - perioperative fluid therapy and, 430–432
Pulmonary contusion
fluid therapy for, 466–467

Pulmonary edema
evaluation for, 462–464

Pulmonary thromboembolism
fluid therapy for, 468

R

Renal diet
in feline ionized hypercalcemia management, 282–283

Respiratory acid-base disorders
in CCU, 351–357 See also specific disorders
brain disease, 353–354
carbon dioxide tension, 352
clinical effects of, 352–353
introduction, 351–352
mechanical ventilation and, 354
respiratory acidosis, 354–355
respiratory alkalosis, 355–356

Respiratory acidosis, 185–189
analysis of, 186
approach to, 189
causes of, 187
in CCU, 354–355
clinical signs of, 187–188
compensation for, 318
introduction, 185
quick reference on, 185–189

Respiratory alkalosis, 181–184
analysis of, 181–182
causes of, 182
in CCU, 355–356
clinical signs of, 182–183
compensation for, 318–319
introduction, 181
quick reference on, 181–184
treatment of, 183–184

Resuscitation
cardiopulmonary
bicarbonate therapy for, 346–347
damage control
in trauma patients, 405–407
delayed
fluid therapy in trauma patients and, 404
hemorrhagic shock, 398
hemostatic
DCR in, 406
hypotensive See Hypotensive resuscitation
physical endpoints of
in trauma patients, 398–399
Resuscitation (continued)
  supranormal
    in trauma patients, 400
Resuscitative injury
  fluid therapy–related
    in trauma patients, 401–402
Right heart
  function of
    fluid therapy in lung disease effects on, 464

S
Sepsis
  hyperlactatemia and, 331
Serum ionized calcium concentration
  changes in
    bicarbonate therapy and, 345
Serum potassium concentration
  changes in
    bicarbonate therapy and, 345
Shock
  hyperlactatemia and, 329–331
Sodium
  abnormalities of
    in kidney disease
      management of, 481
    perioperative fluid therapy and, 429–430
Sodium bicarbonate. See also Bicarbonate therapy
  described, 343
Sodium disorders, 293–312. See also specific types
  osmoregulation in, 295–296
  physiology of, 294–295
  volume regulation in, 295–296
Sodium distribution
  hypernatremia and, 209–210
  hyponatremia and, 213–214
Starling forces
  traditional, 359–360
Strong ion gap
  analysis of, 194–195
  changes in, 195–196
  quick reference on, 194–196
Synthetic colloids
  controversies related to, 415–417

T
TBI
  See Traumatic brain injury (TBI)
TBW
  See Total body water (TBW)
Thrombocytosis
preanalytical errors and abnormalities related to, 269

Thromboembolism
pulmonary
fluid therapy for, 468

TICS
See Trauma-induced capillary leak syndrome (TICS)

Tissue safety factors
in fluid therapy, 360–361

Total body water (TBW), 359
in fluid and electrolyte therapy during vomiting and diarrhea, 508

Toxin(s)
hyperlactatemia-associated, 333
ILE–sensitive, 438

Trauma-induced capillary leak syndrome (TICS)
fluid resuscitation in trauma patients and, 400–401

Trauma patients
fluid therapy in, 397–410
coagulopathy due to, 402
controlled vs. uncontrolled hemorrhage effects on, 399
DCR in, 405–407
delayed resuscitation, 404
hemorrhagic shock resuscitation, 398
hypotensive resuscitation and TBI related to, 404–405
hypotensive resuscitation or permissive hypotension, 403–404
introduction, 397–398
large-volume liberal strategies, 399–400
lethal triad, 402–403
optimal strategy for, 407
physical endpoints of resuscitation, 398–399
restrictive strategies, 403
resuscitative injury, 401–402
supranormal resuscitation, 400
TICS related to, 400–401

Traumatic brain injury (TBI)
hypotensive resuscitation and
in trauma patients, 404–405

U

Ultrasound
in feline ionized hypercalcemia evaluation, 278
in pulmonary edema/volume overload evaluation, 464

Urinary specific gravity (USG)
in feline ionized hypercalcemia evaluation, 278

Urolithiasis diet
in feline ionized hypercalcemia management, 283

USG
See Urinary specific gravity (USG)
Index

V
Ventilation
  mechanical
    in CCU
      respiratory acid-base disorders and, 354
Vitamin A
  in feline ionized hypercalcemia management, 284
Vitamin D
  in feline ionized hypercalcemia management, 284
Volume overload
  evaluation for, 462–464
  isotonic fluids and, 388–389
Volume regulation, 295–296
Vomiting
  fluid and electrolyte therapy during
    combination therapy, 515–516
    crystalloid fluid, 512
    for dehydration, 508–511
    introduction, 505–506, 508
    requirements, 514–515
    route of, 512–54
    TBW and compartmentalization, 508
    treatment failure, 516–517
    updates in, 516

W
Water
  need for, 384–385
Water balance, 293–294
Water disorders, 293–312. See also specific types
  osmoregulation in, 295–296
  physiology of, 294–295
  volume regulation in, 295–296